EUS-guided gastroenterostomy is comparable to enteral stenting with fewer re-interventions in malignant gastric outlet obstruction.
Yen-I Chen, Takao Itoi, Todd H Baron...
https://pubmed.ncbi.nlm.nih.gov/27834024/Actively Recruiting
Led by Northwell Health · Updated on 2026-06-15
32
Participants Needed
4
Research Sites
26 weeks
Total Duration
Gastric outlet obstruction GOO often occurs in cancers involving the periampullary region or distal stomach, leading to severe symptoms like nausea, vomiting, and difficulty eating. This condition affects patients nutritional status and quality of life, making effective therapy important to help them continue cancer treatment. The study compares two methods to treat GOO endoscopic and surgical gastrojejunostomy. Participants will be randomly assigned to receive either a laparoscopic surgical gastrojejunostomy, which creates an anastomosis between the stomach and jejunum, or an endoscopic ultrasound-guided gastrojejunostomy, where a stent is placed between the stomach and small intestine. Both procedures aim to relieve obstruction and improve oral intake. The study collects data before, during, and after procedures, with follow-up points up to one year. During the study, participants complete quality of life questionnaires and undergo clinical assessments including symptom scores, gut function, weight, and performance scales. Data on procedure safety, technical and clinical success, time to oral intake, hospital discharge, and tolerance of chemotherapy are collected. Follow-up visits occur frequently in the first week, then at 30 days, 3 months, 6 months, and 1 year to monitor outcomes and changes in health status.
CONDITIONS
Enteral Anastomosis for the Treatment of Gastric Outlet Obstruction: A Randomized Controlled Study Comparing Endoscopic Versus Surgical Gastrojejunostomy
S
Sumbul Yousafi
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Northwell Health
Lead Sponsor
Rutgers, The State University of New Jersey
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Endoscopic Ultrasound-Guided Gastrojejunostomy | Laparoscopic Surgical Gastrojejunostomy |
|---|---|---|
| What is it? | A minimally invasive endoscopic procedure in which an anastomosis is created between the stomach and jejunum using endoscopic ultrasound guidance, bypassing the obstruction. | A surgical procedure where a bypass is created between the stomach and jejunum using laparoscopy to relieve gastric outlet obstruction caused by advanced GI cancers. |
| Role in the trial | Experimental arm. Participants are randomized to EUS-guided endoscopic gastrojejunostomy. | Active comparator arm. Participants are randomized to laparoscopic gastrojejunostomy. |
| Primary clinical use | Palliation of malignant gastric outlet obstruction, offering a minimally invasive alternative to surgery for restoring oral intake. | Palliation of malignant gastric outlet obstruction, restoring oral intake for patients with unresectable or metastatic GI cancers. |
| How is it performed? | Performed with endoscopy under sedation, an endoscopist uses EUS guidance to place a stent and create a gastrojejunostomy, avoiding open abdominal surgery. | Performed under general anesthesia using laparoscopy, the surgeon makes a stomach-to-jejunum bypass anastomosis to bypass the obstruction. |
| Evidence status | Supported by prospective studies and meta-analyses showing high technical and clinical success, comparable to surgery for restoring oral intake, with potential for quicker recovery. | Established efficacy in restoring oral intake and palliation of GOO. High technical and clinical success, supported by multiple studies and meta-analyses. |
| Important risks | Risks include stent misplacement, bleeding, perforation, infection, and stent migration. Major adverse events are rare but can be serious. | Risks include surgical complications, infection, delayed gastric emptying, and perioperative morbidity. Overall risk is considered acceptable for palliative patients. |
| Important limitations | Long-term durability data are limited. Requires technical expertise and specialized equipment. Stent-related complications may necessitate re-intervention. | Recovery may be slower than minimally invasive alternatives. Risks are higher for patients with poor performance status. May not be suitable for very frail or high-risk patients. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 day (procedure day)
Participants receive either surgical gastrojejunostomy or endoscopic gastrojejunostomy procedures to relieve gastric outlet obstruction. Quality of life questionnaires are completed before the procedure.
1 in-person procedure visit
Duration - 1 year
Participants are monitored at multiple time points post-procedure to assess safety, symptom improvement, and ability to tolerate oral intake. Follow-ups occur 1 to 7 days after the procedure, then at 30 days, 3 months, 6 months, and 1 year.
Multiple follow-up visits as scheduled
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Yen-I Chen, Takao Itoi, Todd H Baron...
https://pubmed.ncbi.nlm.nih.gov/27834024/Marc Barthet, Kenneth F Binmoeller, Geoffroy Vanbiervliet...
https://pubmed.ncbi.nlm.nih.gov/25527056/I Maetani, H Inoue, M Sato...
https://pubmed.ncbi.nlm.nih.gov/8905371/Ryosuke Tonozuka, Takayoshi Tsuchiya, Shuntaro Mukai...
https://pubmed.ncbi.nlm.nih.gov/32962331/Giulio Antonelli, Bojan Kovacevic, John Gásdal Karstensen...
https://pubmed.ncbi.nlm.nih.gov/32505567/Mouen Khashab, Ahmad S Alawad, Eun Ji Shin...
https://pubmed.ncbi.nlm.nih.gov/23299137/Takao Itoi, Kentaro Ishii, Nobuhito Ikeuchi...
https://pubmed.ncbi.nlm.nih.gov/26282674/Edoardo Troncone, Alessandro Fugazza, Annalisa Cappello...
https://pubmed.ncbi.nlm.nih.gov/32390697/Tossapol Kerdsirichairat, Shayan Irani, Juliana Yang...
https://pubmed.ncbi.nlm.nih.gov/30705945/Ana Y Carbajo, Michel Kahaleh, Amy Tyberg
https://pubmed.ncbi.nlm.nih.gov/31567785/Northwell Health
Lead Sponsor
Rutgers, The State University of New Jersey
Collaborating Sponsor